Biotech

ChemoCentryx Inc (NASDAQ:CCXI) shares continued to trade higher and closed 53.58% up to $4.60 on Wednesday, as the company granted marketing rights for CCX168 to Vifor Pharma. ChemoCentryx Inc (NASDAQ:CCXI) has been developing CCX168 for the treatment of conditions including but not limited to anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). This has...

Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares closed 9.87% higher on Friday to $11.13, still within the lower part of its 52-week range of $9.81 to $25.04. Concert Pharmaceuticals Inc (NASDAQ:CNCE) shares dropped sharply at the start of May even after the company reported its CTP-543 drug for the treatment of alopecia...

Puma Biotechnology Inc (NYSE:PBYI) shares rose 17.22% on Friday to $26.21 as 1.75 million shares traded hands compared to an average trading volume of  778,890 shares. Puma Biotechnology Inc (NYSE:PBYI) reported its quarterly earnings data earlier in the week, showing a loss of $1.28 per share versus expectations of a $1.99...

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) shares were up 17.06% to $7.48 on Monday even after the company reported a loss for the first quarter of the year. Vitae Pharmaceuticals Inc (NASDAQ:VTAE) is a biotechnology company focused on  discovering and developing small molecule drugs for diseases. In particular, the company is engaged in developing a portfolio...

Coherus Biosciences Inc (NASDAQ:CHRS) shares advanced 15.58% to $18.85 on Tuesday following a favorable decision from the US Patent and Trademark Office for '135 IPR. Coherus Biosciences Inc (NASDAQ:CHRS) is a late-stage clinical biologics platform company focused on the global biosimilar market. The company develops and commercializes biosimilar products segment organized around therapeutic franchises. The...